vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Stabilis Solutions, Inc. (SLNG). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $13.3M, roughly 1.4× Stabilis Solutions, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -2.0%, a 1.1% gap on every dollar of revenue. On growth, Stabilis Solutions, Inc. posted the faster year-over-year revenue change (-23.3% vs -25.7%). Stabilis Solutions, Inc. produced more free cash flow last quarter ($-2.5M vs $-15.8M). Over the past eight quarters, CytomX Therapeutics, Inc.'s revenue compounded faster (-15.9% CAGR vs -18.1%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Stabilis Solutions, Inc.SLNGEarnings & Financial Report
Stabilis Solutions, Inc. is a leading North American small-scale liquefied natural gas (LNG) producer and distributor. It supplies LNG fuel, cryogenic services, and full-cycle energy solutions to industrial, remote power, transportation, and commercial clients across the United States and Canada, advancing low-emission energy transition efforts.
CTMX vs SLNG — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $13.3M |
| Net Profit | $-154.0K | $-262.0K |
| Gross Margin | — | 24.7% |
| Operating Margin | -6.9% | -2.4% |
| Net Margin | -0.8% | -2.0% |
| Revenue YoY | -25.7% | -23.3% |
| Net Profit YoY | 97.6% | -112.4% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.3M | ||
| Q3 25 | — | $20.3M | ||
| Q2 25 | $18.7M | $17.3M | ||
| Q1 25 | $50.9M | $17.3M | ||
| Q4 24 | $38.1M | $17.3M | ||
| Q3 24 | $33.4M | $17.6M | ||
| Q2 24 | $25.1M | $18.6M | ||
| Q1 24 | $41.5M | $19.8M |
| Q4 25 | — | $-262.0K | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-154.0K | $-613.0K | ||
| Q1 25 | $23.5M | $-1.6M | ||
| Q4 24 | $18.9M | $2.1M | ||
| Q3 24 | $5.7M | $997.0K | ||
| Q2 24 | $-6.5M | $27.0K | ||
| Q1 24 | $13.8M | $1.5M |
| Q4 25 | — | 24.7% | ||
| Q3 25 | — | 27.6% | ||
| Q2 25 | — | 26.5% | ||
| Q1 25 | — | 26.2% | ||
| Q4 24 | — | 28.5% | ||
| Q3 24 | — | 28.3% | ||
| Q2 24 | — | 27.1% | ||
| Q1 24 | — | 31.6% |
| Q4 25 | — | -2.4% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | -6.9% | -2.4% | ||
| Q1 25 | 44.4% | -9.7% | ||
| Q4 24 | 46.4% | 12.8% | ||
| Q3 24 | 12.3% | 5.0% | ||
| Q2 24 | -33.7% | 2.4% | ||
| Q1 24 | 28.1% | 7.8% |
| Q4 25 | — | -2.0% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | -0.8% | -3.5% | ||
| Q1 25 | 46.2% | -9.2% | ||
| Q4 24 | 49.6% | 12.2% | ||
| Q3 24 | 17.2% | 5.7% | ||
| Q2 24 | -26.0% | 0.1% | ||
| Q1 24 | 33.3% | 7.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | — | $-0.03 | ||
| Q1 25 | — | $-0.09 | ||
| Q4 24 | — | $0.12 | ||
| Q3 24 | — | $0.05 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | — | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $7.5M |
| Total DebtLower is stronger | — | $7.9M |
| Stockholders' EquityBook value | $119.9M | $66.7M |
| Total Assets | $175.1M | $83.1M |
| Debt / EquityLower = less leverage | — | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $7.5M | ||
| Q3 25 | — | $10.3M | ||
| Q2 25 | $49.0M | $12.2M | ||
| Q1 25 | $47.6M | $9.0M | ||
| Q4 24 | $38.1M | $9.0M | ||
| Q3 24 | $40.6M | $12.4M | ||
| Q2 24 | $43.2M | $11.5M | ||
| Q1 24 | $36.2M | $8.3M |
| Q4 25 | — | $7.9M | ||
| Q3 25 | — | $8.3M | ||
| Q2 25 | — | $7.6M | ||
| Q1 25 | — | $8.3M | ||
| Q4 24 | — | $8.9M | ||
| Q3 24 | — | $9.3M | ||
| Q2 24 | — | $8.6M | ||
| Q1 24 | — | $9.1M |
| Q4 25 | — | $66.7M | ||
| Q3 25 | — | $66.7M | ||
| Q2 25 | $119.9M | $65.5M | ||
| Q1 25 | $25.0M | $65.9M | ||
| Q4 24 | $-456.0K | $67.0M | ||
| Q3 24 | $-23.5M | $65.4M | ||
| Q2 24 | $-31.2M | $63.7M | ||
| Q1 24 | $-31.7M | $63.2M |
| Q4 25 | — | $83.1M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | $175.1M | $83.2M | ||
| Q1 25 | $98.5M | $83.1M | ||
| Q4 24 | $120.5M | $85.6M | ||
| Q3 24 | $139.0M | $89.3M | ||
| Q2 24 | $159.2M | $82.6M | ||
| Q1 24 | $184.7M | $80.6M |
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 0.13× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.13× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $669.0K |
| Free Cash FlowOCF − Capex | $-15.8M | $-2.5M |
| FCF MarginFCF / Revenue | -84.6% | -18.6% |
| Capex IntensityCapex / Revenue | 0.1% | 23.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $462.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $669.0K | ||
| Q3 25 | — | $2.4M | ||
| Q2 25 | $-15.8M | $4.5M | ||
| Q1 25 | $-21.0M | $1.0M | ||
| Q4 24 | $-19.9M | $2.2M | ||
| Q3 24 | $-20.7M | $2.6M | ||
| Q2 24 | $-19.5M | $5.0M | ||
| Q1 24 | $-26.0M | $3.9M |
| Q4 25 | — | $-2.5M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | $-15.8M | $3.9M | ||
| Q1 25 | $-21.2M | $538.0K | ||
| Q4 24 | $-20.0M | $-3.4M | ||
| Q3 24 | $-20.7M | $1.2M | ||
| Q2 24 | $-19.6M | $3.7M | ||
| Q1 24 | $-26.2M | $3.1M |
| Q4 25 | — | -18.6% | ||
| Q3 25 | — | -7.3% | ||
| Q2 25 | -84.6% | 22.4% | ||
| Q1 25 | -41.6% | 3.1% | ||
| Q4 24 | -52.5% | -19.7% | ||
| Q3 24 | -62.1% | 7.1% | ||
| Q2 24 | -78.2% | 19.7% | ||
| Q1 24 | -63.1% | 15.5% |
| Q4 25 | — | 23.7% | ||
| Q3 25 | — | 19.1% | ||
| Q2 25 | 0.1% | 3.7% | ||
| Q1 25 | 0.2% | 2.8% | ||
| Q4 24 | 0.2% | 32.3% | ||
| Q3 24 | 0.1% | 7.4% | ||
| Q2 24 | 0.4% | 7.4% | ||
| Q1 24 | 0.3% | 4.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.14× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | 1.03× | ||
| Q3 24 | -3.61× | 2.56× | ||
| Q2 24 | — | 186.59× | ||
| Q1 24 | -1.89× | 2.67× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SLNG
| Natural Gas Gathering Transportation Marketing And Processing | $11.1M | 84% |
| Other | $1.3M | 10% |
| Services | $897.0K | 7% |
